Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM295PR)

• Drug Name: Ofatumumab Drug Info
• Synonyms: Arzerra (TN)

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Approved	[1]
Small lymphocytic lymphoma	2A82.0	Approved	[2]
Diffuse large B-cell lymphoma	2A81	Phase 3	[1]
Non-hodgkin lymphoma	2B33.5	Phase 3	[3]
Rheumatoid arthritis	FA20	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM295PR

Molecule-Related Drug Atlas

Drug(s) Targeting Leukocyte surface antigen Leu-16 (CD20)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[5]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[6]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[7]
Ibritumomab	DMG594T	Non-hodgkin lymphoma	2B33.5	Approved	[8]
Rituximab	DM1YVZT	Central nervous system non-hodgkin lymphoma		Approved	[9]
Ublituximab	DMHTY9W	Multiple sclerosis	8A40	Approved	[10]
Tositumomab	DMMYZ3D	Non-hodgkin lymphoma	2B33.5	Approved	[8]
Obinutuzumab	DM3BVAE	Chronic lymphocytic leukaemia	2A82.0	Approved	[11]
Rituximab	DM1YVZT	Central nervous system non-hodgkin lymphoma		Approved	[12]
Ocrelizumab	DMEZ2KH	Diffuse large B-cell lymphoma	2A81	Approved	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	Not Available	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6778).
• [2] Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019 Dec;94(12):1353-1363.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [7] Clinical pipeline report, company report or official report of Genmab.
• [8] Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
• [9] [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
• [10] The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
• [12] Clinical pipeline report, company report or official report of Genentech (2009).
• [13] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.